Navigation Links
Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals' Board of Directors

CAMBRIDGE, Mass., May 5 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Michael D. Taylor, Ph.D., has joined the company's board of directors. Dr. Taylor is president and chief executive officer of Ensemble Discovery Corporation, a Cambridge, Massachusetts-based biotechnology company developing novel classes of therapeutics and bioassays using its proprietary DNA Programmed Chemistry(TM) (DPC(TM)) platform.

"Mike is a terrific addition to our board," said Cequent President and CEO, Peter Parker. "With more than 20 years in the pharmaceutical industry, his extensive experience ranges from drug discovery -- leading early and late-stage development projects across multiple therapeutic areas, including Lipitor(R) and Neurontin(R) -- to licensing, business development, and managing R&D alliances with pharmaceutical and biotech partners. His counsel and strong industry relationships will be valuable assets to Cequent as we continue to move our clinical candidates from pre-clinical development toward a successful IND submission with the FDA."

Dr. Taylor joined Ensemble Discovery Corporation in July of 2007. Previously, he was senior vice president for Pfizer's Global R&D division. In addition to his R&D experience, he is active in investor development, government affairs, and public policy affecting the pharmaceutical industry. Until 2003, he was adjunct professor of medicinal chemistry at the College of Pharmacy at the University of Michigan, where he was active in teaching medicinal chemistry and biopharmaceutics. Dr. Taylor has authored or coauthored 65 manuscripts and published abstracts, and holds six patents.

Dr. Taylor has a doctorate in medicinal chemistry from the State University of New York at Buffalo and was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania.

About Cequent Pharmaceuticals, Inc.

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases -- from inflammatory diseases to cancer -- based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi(TM)). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. For more information, visit

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
11. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
Post Your Comments:
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)... 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual ... 11:00 a.m. Israel time, at the law offices ... Street, 36 th Floor, Tel Aviv, Israel . ... and Izhak Tamir to the Board of Directors; , ... , approval of an amendment to certain terms of options granted ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Inc., on being named to Deloitte's 2015 Technology Fast 500 list of the ... manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic tooth ...
Breaking Biology Technology:
(Date:10/29/2015)... -- Daon, a global leader in mobile biometric authentication ... version of its IdentityX Platform , IdentityX v4.0. ... have already installed IdentityX v4.0 and are seeing ... UAF certified server component as an option and ... These customers include some of the largest and most ...
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
Breaking Biology News(10 mins):